论文部分内容阅读
目的探讨罗格列酮对2型糖尿病内皮依赖性血管舒张功能的影响。方法选择2型糖尿病患者60例为研究对象,分别给予二甲双胍、二甲双胍联合罗格列酮、罗格列酮治疗,另选择20例健康体检者作为对照组,回顾性分析治疗前后三组内皮依赖性血管舒张功能及其他相关指标变化。结果联合组和罗格列酮组HDL-C治疗前后比较,差异有统计学意义(P<0.05)。治疗后三组FPG、HbA1c、FINS、HOMR-IR与治疗前比较,差异有统计学意义(P<0.05)。联合组和罗格列酮组NO、高敏C反应蛋白、TNF-α治疗后各指标与治疗前比较差异有统计学意义(P<0.05)。联合组和罗格列酮组治疗后FMD和EID与治疗前比较,差异有统计学意义(P<0.05)。结论 2型糖尿病患者存在血管内皮依赖性舒张功能受损,罗格列酮能够升高NO水平,改善内皮依赖性舒张功能,从而对血管发挥保护作用。
Objective To investigate the effect of rosiglitazone on endothelium-dependent vasodilatation in type 2 diabetic patients. Methods Sixty patients with type 2 diabetes mellitus (T2DM) were selected as study subjects. Metformin, metformin combined with rosiglitazone and rosiglitazone respectively. Another 20 healthy subjects were selected as control group. The endothelium-dependent Vasodilatation and other related changes in indicators. Results The HDL-C in the combination group and rosiglitazone group had significant difference before and after treatment (P <0.05). The levels of FPG, HbA1c, FINS and HOMR-IR in three groups after treatment were significantly different from those before treatment (P <0.05). NO, high-sensitivity C-reactive protein and TNF-α in the combination group and rosiglitazone group were significantly different from those before treatment (P <0.05). The difference of FMD and EID between the combined group and rosiglitazone group before treatment was statistically significant (P <0.05). Conclusion In patients with type 2 diabetes, endothelium-dependent vasodilatation is impaired. Rosiglitazone may increase NO level and improve endothelium-dependent vasodilatation, which may play a protective role on blood vessels.